Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides

Clinical Chemistry

Volumn 44, Issue 11, 1998, Pages 2290-2300

  Christgau, Stephan ^a   Rosenquist, Christian ^a   Alexandersen, Peter ^b   Bjarnason, Nina Hannover ^b   Ravn, Pernille ^b   Fledelius, Christian ^a   Herling, Christian ^a   Qvist, Per ^a   Christiansen, Claus ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; ESTRADIOL PLUS NORETHISTERONE ACETATE; IBANDRONIC ACID; PIPERAZINE ESTRONE SULFATE; TIBOLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OSTEOLYSIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; TREATMENT OUTCOME;

EID: 0031761305     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.11.2290     Document Type: Article

References (30)

1. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993;25:385-93.
2. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59:S2-9.
3. 1 chain of type I collagen. J Biol Chem 1997;272:9755-63.
4. Cloos PAC, Bonde M, Fledelius C. Christgau S, Christiansen C. Isomerized molecules in serum derived from bone resorption. In: Papapoulos SE, Pols HAP, Johnston CC, Delmas PD, eds. Osteoporosis 1996. Amsterdam: Eisevier Science BV, 1996:227-31.
5. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
6. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late post menopause. J Clin Endocrinol Metab 1994;79:1693-700.
7. Ravn P, Clemmensen B, Juel Riis B, Overgaard K, Christiansen C. The effect of bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled, dose-finding study. Bone 1996;19: 527-33.
8. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR. Comparison of semi-quantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11:984-96.
9. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 1993;5:255-60.
10. Risteli J, Risteli L. Assays of type I pro-collagen domains and collagen fragments: problems to be solved and future trends. Scand J Clin Lab Investig 1997;57:105-13.
11. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. The Serum CrossLaps One Step ELISA. The first quantitative determination in serum of degradation products from C-terminal telopeptides of type I collagen from bone using monoclonal antibodies. Clin Chem 1998;44:2293-301.
12. Rozenberg S, Kroll M, Pastijn A, Van dromme J. Osteoporosis prevention and treatment with sex hormone replacement therapy. Clin Rheumatol 1995;14:14-7.
13. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
14. Ribot CA, Tremollieres FA. Effect of estrogens on bone and other systems and hormonal substitute treatment. Curr Opin Rheumatol 1997;9:362-9.
15. Rodan GA, Fleish H. Bisphosphonates. Mechanism of action. J Clin Investig 1996;97:2692-6.
16. Compston JE. Prevention and management of osteoporosis. Current trends and future prospects. Drugs 1997;53:727-35.
17. Weinerman SA, Bockman RS. Medical therapy of osteoporosis. Orthop Clin N Am 1990;21:109-24.
18. Bjarnason NH, Bjamason K, Haarbo J, Rosenquist C, Christianser C. Tibolone. Prevention of bone loss in late post-menopausal women. J Clin Endocrinol Metab 1996;81:2419-22.
19. Bjamason NH, Bjamason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997;20:151-5.
20. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
21. Eyre D. Collagen cross-linking amino acids. Methods Enzymol 1987;144:115-39.
22. Prockop DJ, Kivirikko KI. Collagens. Molecular biology, disease and potentials for therapy. Annu Rev Biochem 1995;64:403-34.
23. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994;24:81-94.
24. Risteli J, Eloma I, Niemi S, Novamo A, Risteli L. Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
25. Pedrazzoni M, Alfano FS, Gatti C, Fantuzzi M, Girasole G, Campanini C, et al. Acute effect of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995;57: 25-9.
26. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 1995;41:1592-8.
27. Risteli J, Sassi ML, Eriksen M, Niemi S, Jason P, Risteli L. Epitope of the assay for the carboxy-terminal telopeptide of human type I collagen (ICTP). J Bone Miner Res 1997;12(Suppl 1):S498.
28. Foged NT, Delaisse JM, Hou P, Lou H, Sato T, Winding B, Bonde M. Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immuno-sorbent assay. J Bone Miner Res 1996;11:226-37.
29. Richard-Blum S, Chossgros P, Guerret S, Trepo C, Grimaud JA, Chevallier M. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoing liver fibrosis. Clin Chim Acta 1996;248:187-95.
30. Chesnut CH III, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston CC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.